Reuters logo
BRIEF-Regeneron says Sanofi plant used to fill drugs now deemed acceptable
January 10, 2017 / 12:31 AM / a year ago

BRIEF-Regeneron says Sanofi plant used to fill drugs now deemed acceptable

Jan 9 (Reuters) - Regeneron Pharmaceuticals Inc

* Regeneron CEO says Sanofi plant that will fill atopic dermatitis drug awaiting U.S. approval decision deemed acceptable

* Regeneron CEO predicts PBMs will pay for Dupixent atopic dermatitis drug once approved

* Regeneron ceo says expects to file for U.S. approval of dupilumab for asthma in Q4

* Regeneron sees 2017 reimbursement of commercialization expenses from Sanofi of $400 million to $450 million

* Regeneron sees 2017 capital expenditures $375 million to $450 million Source text for Eikon: Further company coverage: (Reporting By Bill Berkrot)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below